Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Purpose
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Conditions
- Sickle Cell Disease
- Measles Vaccination
- Sickle Cell Anemia
Eligibility
- Eligible Ages
- Between 6 Months and 6 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants with confirmed Sickle Cell Disease. 2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines. 3. Willing and able to provide informed consent 4. Ability to comply with study related evaluations and follow-up visits.
Exclusion Criteria
- Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Second Measles Vaccine (MV2) | Participants who receive second measles vaccine. | |
| First Measles Vaccine (MV1) | Participants who obtain the first measles vaccine. |
Recruiting Locations
Cincinnati Children's Hospital Medical Center
Cincinnati 4508722, Ohio 5165418 45229
Cincinnati 4508722, Ohio 5165418 45229
More Details
- Status
- Recruiting
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Detailed Description
Families of infants with SCD who are eligible for a measles vaccine per standard care will be contacted to discuss enrollment in the study. One cohort will be evaluated for response to the first measles vaccine (MV1) and another cohort will be evaluated for response to the second measles vaccine (MV2). Blood samples will be collected from participants prior to measles vaccination and then again at 4 and 8 weeks after vaccination.